Resources

For the latest in biologics & tides, sign up for our monthly newsletter to be among the first to receive exclusive insights, in-depth market analyses, and expert articles directly to your inbox

Pioneers of COVID-19 mRNA Vaccine Win Nobel Prize

Professors Katalin Karikó and Drew Weissman have been awarded the 2023 Nobel Prize in Medicine for their contributions to the development of the COVID-19 mRNA vaccine.
Antibody & Protein Engineering

FDA Approves Takeda’s Subcutaneous Ulcerative Colitis mAb

The company can now sell their biologic for ulcerative colitis in a subcutaneous form on the US market.
Antibody & Protein Engineering

Navigating the Pharma R&D Regulatory Landscape 2023

Our ‘Navigating the Regulatory Landscape’ eBook has been designed to provide you with invaluable insights into the intricacies of regulations & policies surrounding the challenges and opportunities of Real-World Data, genome editing, biomedical informatics, manufacturing and many more.
Oligo Chemistry

How Do Regulatory Considerations Impact the Clinical Development of Oligonucleotide Therapies?

What are the regulatory considerations that need to be made in the clinic for oligonucleotide therapies? What's the existing guidance for this emerging modality?
Peptide Chemistry

Trends and Challenges in Peptide Bioanalysis and Production

Here, we investigate some of the main trends and challenges in peptide bioanalysis such as non-specific binding, and look at how they can be circumvented.
Antibody & Protein Engineering

Amgen and Synaffix Pen $2 Billion

Amgen and Synaffix's partnership aims to revolutionise cancer treatment by developing highly targeted antibody-drug conjugates (ADCs).
Oligo Chemistry

Friedrich Miescher: The Pioneer of Nucleic Acid Discovery

As medical research that is founded on nucleic acids continues to progress, we take a step back to look at the man who first discovered nucleic acids.
Antibody & Protein Engineering

F-star and Takeda Collaborate to Pave the Way for Next-Generation Cancer Therapies  

F-star Therapeutics and Takeda are partnering to develop next-generation multi-specific antibodies for cancer immunotherapy, building on F-star's advanced platforms.

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things biologics